

Disclaimer

Organizations may not re-use material presented at this AMCP session for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.





Welcome

Edith A. Rosato, RPh, IOM

Chairman, Board of Trustees

Academy of Managed Care Pharmacy Foundation

John Mackowiak, PhD - Symposium Moderator

VP, Pharmacy & Education, AMCP Editor, Journal of Managed Care & Specialty Pharmacy,
Academy of Managed Care Pharmacy





Symposium Sponsors

AMCP Foundation would like to thank the following companies for their support of the symposium:



biogen idec









Program Objectives

The AMCP Foundation is focusing on an important and critical health care issue under the theme "Specialty Pharmacy and Patient Care: Are We at a Tipping Point?"

The potential for improved patient care and improved outcomes through the use of specialty pharmaceuticals holds great promise. However, this potential is facing intense scrutiny centered primarily on the cost and challenges of access to specialty pharmaceuticals.


The AMCP Foundation will examine these and related issues as part of the symposium. Topics to be addressed include:

- 1. Integrating the pharmacy and medical benefit—what are the upsides and downsides, opportunities and barriers; how do we do it, who has to be convinced? How does it promote patient outcomes?
- 2. The specialty drugs conundrum: why is something so great so expensive? How do we maximize access and affordability to take advantage of the promise of specialty pharmaceutical therapy? How do we reward innovation?
- 3. What can health plans do to enhance proper utilization of specialty drugs?
- 4. What are payer concerns, both private and public, with use of specialty pharmaceuticals?
- 5. What are patient and caregiver perspectives and the public policy implications?

In addition to the live symposium presentations, the entire program will be video- taped and repurposed, with presentations and handouts indexed, and will be posted on the AMCP Foundation website after the Nexus Conference. A summary of symposium proceedings, as an abbreviated written proceeding document, also will be produced and made available to the public.







The High Cost of Curing Hepatitis C: This is just the tip of the iceberg

Medicaid directors must be wise stewards of the taxpayer dollar, and make decisions every day about how to prioritize many underfunded needs.





The High Cost of Curing Hepatitis C: This is just the tip of the iceberg

The high cost and widespread need for Sovaldi in the Medicaid population pose a unique challenge to limited budgets.





The High Cost of Curing Hepatitis C: This is just the tip of the iceberg

Neither the cost, nor ultimately the access to treatment, can be controlled by states, because Medicaid doesn't resemble a free market in this area.





The High Cost of Curing Hepatitis C: This is just the tip of the iceberg

Federal action will be necessary in the short term to resolve this conundrum.





The High Cost of Curing Hepatitis C: This is just the tip of the iceberg

Because the pharmaceutical pipeline is full of innovative yet likely expensive treatments, broader national debates will be needed to help focus the country's priorities.





QUESTIONS?



